Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3

Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3

<b>Background:</b> Targeted therapies (e.g., ibrutinib) have markedly improved chronic lymphocytic leukemia (CLL) management; however, ~20% of patients experience disease relapse, suggesting the inadequate depth and durability of these front-line strategies. Moreover, immunotherapeutic s...

Full description

Saved in:
Bibliographic Details
Main Authors: Elizabeth Schmitz, Abigail Ridout, Audrey L. Smith, Alexandria P. Eiken, Sydney A. Skupa, Erin M. Drengler, Sarbjit Singh, Sandeep Rana, Amarnath Natarajan, Dalia El-Gamal
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Biomedicines
Subjects:
chronic lymphocytic leukemia (CLL)
SpiD3
immunogenic cell death (ICD)
damage-associated molecular patterns (DAMPs)
ferroptosis
oxidative stress
Online Access:https://www.mdpi.com/2227-9059/12/12/2857
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items